pp-257 Cream
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Dermatological disease, Genitourinary disease, Immune disorder, Inflammatory disease, Neurological disease
Clinical stage: Phase 2
Modality: Small molecule
Mechanism & Target: Immunomodulator, Pathway modulator, Dermatological agent, Renal system agent, Protein target
Route & form: Topical
Differentiation: Novel Chemical Structure Irreversible covalent inhibitor, unique RNH–N conjugation, absent in marketed drugs, and nitrogen atom distribution
Manufacturer #39672
A clinical-stage biopharmaceutical company focused on neurology. Developing a small molecule therapeutic targeting neurology with global development focus. Pipeline positioned for regulatory advancement in key markets.
None